Key result
New anticoagulants and device therapies offer the potential for greater stroke reductions with a lower incidence of bleeding for patients with atrial fibrillation compared to warfarin.
Why the study?
Do new drugs and treatment strategies improve stroke prophylaxis and reduce bleeding complications compared to warfarin in patients with atrial fibrillation?
Do new drugs and treatment strategies improve stroke prophylaxis and reduce bleeding complications compared to warfarin in patients with atrial fibrillation?
New stroke prophylaxis options in atrial fibrillation may offer better tailoring of treatments to high-risk patients while reducing bleeding complications compared to warfarin.
Answers are grounded in this paper and cite their sources.
May support tailored AF stroke prevention with less bleeding; leaves open need for direct comparative trials.
Atrial Fibrillation (AF) is an epidemic that is increasing in size and scope. AF can have many symptoms and cause a variety of negative health impacts.The most important health risk of AF is the increased risk of stroke and systemic thromboembolism.Oral anticoagulation with warfarin has been the gold standard for stroke risk reduction in AF, but new drugs and treatment strategies for AF are changing clinical practice. These new advances could offer better tailoring of treatments to patients with high risk of stroke while reducing the potential bleeding complications.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2013) conducted a review in Atrial Fibrillation. New oral anticoagulants and device therapies vs. Warfarin or Aspirin was evaluated on Stroke and systemic thromboembolism. New anticoagulants and device therapies offer the potential for greater stroke reductions with a lower incidence of bleeding for patients with atrial fibrillation compared to warfarin.
Synapse has enriched 10 related papers. Consider them for comparative context: